Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Furmonertinib in Resectable EGFR-Mutant Stage II–IIIB Lung Adenocarcinoma
ChiCTR2600123002Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of furmonertinib in Non-small cell lung cancer adenocarcinoma (NSCLC) and bronchial carcinoma (3 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Major pathological response rate (MPR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2600123002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123002.